Bristol-Myers Squibb has challenged the recently released report by the Institute for Clinical and Economic Review that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma.
Bristol-Myers Squibb (BMS) has challenged the recently released report by the Institute for Clinical and Economic Review (ICER) that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma (MM). In a press release, the company said “We fundamentally disagree with ICER’s approach to value assessment, which led to the questionable conclusions outlined in its report.”
The company’s new treatment for MM, elotozumab (Empliciti), was 1 of 3 agents approved right before the annual meeting of the American Society of Hematology (ASH) in December 2015. Elotozumab, daratumumab (Darzalex), and ixazomib (Ninlaro) were all reviewed during a joint session held by the FDA and ASH. Left with multiple choices, how best can clinicians choose the treatment for their patients in combination with the standard of care?
The ICER report focused on 6 different combination treatments to be used as second or third-line treatments in relapsed/refractory patients with MM. However, the report concluded that while some of these combinations are promising, it’s too early to determine their cost-effectiveness.
BMS has raised objections to several sections of the report, with the patient perspective in mind:
3. It does not adhere to established Health Technology Assessment (HTA) best practices. HTA should be based on a clear, transparent, sophisticated and, differentiated view of value. It should include a clear understanding of disease management and indirect benefits.
“While assessments of cost-effectiveness may prove useful in comparing treatments, they have significant limitations, and the lack of available mature data sources preclude the drawing of valid conclusions,” the release claims.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More